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A B S T R A C T
Purpose
To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17-
demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials.
Patients and Methods
This was a phase I study examining a once-weekly dosing schedule of 17-AAG. Thirty
patients with advanced malignancies were treated.
Results
The highest dose level reached was 450 mg/m2/week. The dose-limiting toxicities (DLTs)
encountered were grade 3 diarrhea in three patients (one at 320 mg/m2/week and two at 450
mg/m2/week) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m2/week.
Two of nine DLTs were at the highest dose level. Two patients with metastatic melanoma
had stable disease and were treated for 15 and 41 months, respectively. The dose versus
area under the curve–relationship for 17-AAG was linear (r2  .71) over the dose range 10 to
450 mg/m2/week, with peak plasma concentrations of 8,998 g/L (standard deviation, 2,881)
at the highest dose level. After the demonstration of pharmacodynamic changes in
peripheral blood leukocytes, pre- and 24 hours post-treatment, tumor biopsies were
performed and demonstrated target inhibition (c-RAF-1 inhibition in four of six patients, CDK4
depletion in eight of nine patients and HSP70 induction in eight of nine patients) at the dose
levels 320 and 450 mg/m2/week. It was not possible to reproducibly demonstrate these
changes in biopsies taken 5 days after treatment.
Conclusion
It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with
therapeutic plasma concentrations and target inhibition for 24 hours after treatment and
some indications of clinical activity at the dose level 450 mg/m2/week. We recommend this
dose for phase II clinical trials.
J Clin Oncol 23:4152-4161. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Heat shock protein 90 (HSP90) is a highly
conserved molecular chaperone that plays
an important role in regulating post-
translational folding, stability, and function
of its client proteins.1 Client proteins impor-
tant to cancer include steroid hormone re-
ceptors (progesterone receptor,2 androgen
receptor3), protein kinases (ERB-B2,4 BCR-
ABL,5 c-RAF-1,6 AKT/PKB,7 and CDK48),
mutant p539 and telomerase h-TERT.10 Sta-
bilization and regulation of client proteins
by HSP90 is dependent on binding and hy-
drolysis of ATP at the N-terminus,11 and
inhibition of this activity leads to degrada-
tion of client proteins by the ubiquitin-
proteasome pathway.12
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Benzoquinone ansamycins, such as geldanamycin and
17-allylamino, 17-demethoxygeldanamcyin (17-AAG), com-
pete with ATP for binding to the N-terminus of HSP90.13
Geldanamcyin showed promising preclinical activity in vitro,
but was found to be hepatotoxic in animal models and could
not be tested in humans.14 17-AAG is a structurally similar
analog with a better toxicity profile and is the first HSP90
inhibitor to enter clinical trials.15 17-AAG has shown a prom-
ising preclinical profile with a mean growth inhibitory IC50
of approximately 120 nmol/L in the National Cancer Insti-
tute (NCI) 60 human tumor cell line panel. It induces
apoptosis and cell cycle arrest in cancer cells16 and has
shown activity in a variety of xenograft models.17-19
The primary aims of this phase I study were to deter-
mine the toxicity, pharmacokinetic profile, and pharmaco-
dynamic effects of 17-AAG. The secondary end point was to
assess disease response. The phase I trial was conducted
with the support of the Cancer ResearchUKDrugDevelop-
ment Office (London, United Kingdom), and 17-AAG
(NSC330507) was supplied by the NCI (National Institutes
of Health, Bethesda, MD).
PATIENTS AND METHODS
Trial Conduct
The trial was conducted under the auspices of Cancer Re-
search UK at the Royal Marsden Hospital (Sutton). The protocol
was reviewed by theCancer ResearchUKprotocol review commit-
tee and the clinical research and ethics committees of the Royal
Marsden Hospital. Patients signed an informed consent for entry
into the study. Separate consent formswere signed before pre- and
post-treatment biopsies at higher dose levels.
Inclusion and Exclusion Criteria
The trial included patients with histologically proven malig-
nancy refractory to conventional treatment who had not had
chemotherapy or hormonal therapy in the last 4 weeks. Patients
needed to be 18 years of age or older, have a WHO performance
status of 0 to 2, and a life expectancy of at least 12 weeks. Adequate
organ function included a hemoglobin  10 mg/dL, absolute
neutrophil count 1 0.5 109/L, platelets 100 X109/L, plasma
creatinine 130mmols/L or gromerular filtration rate assessed by
ethylene diamine tetraacetic acid clearance 60 mL/min, plasma
bilirubin  17 umol/L and a normal AST/ALT or an AST/ALT
2.5 upper limit of normal if there were known liver metastases.
Exclusion criteria included pregnancy or lactation in women, a
myocardial infarction in the last 6 months, abnormal ECG with a
left ventricular ejection fraction less than 45%, and history of an
egg allergy.
Toxicity
Toxicity was monitored by NCI Common Toxicity Criteria
version 2. Definitions of dose-limiting toxicities (DLTs) included
a grade 4 neutropenia and/or febrile neutropenia, grade 4
thrombocytopenia or grade 3 thrombocytopenia with fever,
grade 3 or 4 nonhematologic toxicity excluding grade 3 nausea
and/or vomiting, or grade 3 asymptomatic reversible rise in
liver transaminases (AST/ALT).
Dose Expansion
The starting dose, 10mg/m2, was determined by one tenth of
the dose lethal to 10% of animals (LD10) in mice. Three patients
would be included in each cohort and the dose doubled until
there was a drug-related grade 1 renal or cardiac toxicity, or two
episodes of other grade 2 nonhematologic toxicities following
which 40% dose increments would be employed. If a DLT was
observed, the cohort would be expanded to six patients. The
maximum-tolerated dose (MTD) would be defined when two
or more of six patients at a dose level experienced DLTs.
Characterization of Response
Tumor assessments were performed before treatment and
every 8 weeks thereafter. Responses in target lesions were assessed
by the WHO criteria.
Drug Administration
17-AAG and the egg phospholipid diluent were supplied by
theNCI. The final concentration for intravenous use was 1mg/mL
17-AAG in 4% dimethyl sulfoxide (DMSO) and 5% dextrose, and
the drug was administered over 15 to 200 minutes. 17-AAG was
administered once a week without a break. One cycle of chemo-
therapy was defined as 4 weeks.
Pharmacokinetic Sampling and Analysis
Blood samples were drawn predose, at infusion end, and then
at predetermined intervals for 24 hours at the starting dose and up
to 48 hours at the dose level 160mg/m2/week and above. 17-AAG,
its metabolite 17-AG (17-amino, 17-demethoxygeldanamycin)
and the internal standard -napthoflavone were extracted
from 500L human plasma using solid phase extraction. Extracts
were dried and redissolved in 150 L 50% acetonitrile/water.
Analysis was carried out by high-performance liquid chromatog-
raphy (HPLC) with UV detection at 330 nm on a Thermosepara-
tions system (Thermo Electron, San Jose, CA). HPLC was
performed using a Supelcosil 3 m 150 4.6 mm internal diam-
eter LC-18 column with a Supelguard LC-18 (Supelco; Sigma-
Aldrich, Dorset, United Kingdom) and a gradient mobile phase
containing water and acetonitrile. The assay was linear over the
range 10 to 2,400 ng/mL with quality controls (n 2) analyzed at
20, 200, 800, and 1,600 ng/mL. Acceptance criteria were estab-
lished according to published guidelines.20
Pharmacodynamic Analysis
Procedures were based on validated molecular markers.19,21
Peripheral blood leukocytes (PBLs) were sampled for varying pe-
riods (24 to 96 hours) at dose levels of 10 to 450 mg/m2/week.
Tumor biopsies were performed before and 1 to 5 days after
treatment in 12 patients at dose levels of 320 to 450 mg/m2/week.
Tumor sampleswere obtained by excision biopsy in 6 patientswho
had superficial skin tumors and by ultrasound-guided core biop-
sies (16 G Tru-Cut needle; UK Medical, Sheffield, UK) in five
patients who had visceralmetastasis. Tumor cells were obtained in
one patient with acscites by centrifugation (5,000 g for 5minutes).
The samples were arbitrarily divided in two sections (approxi-
mately 20% and 80%) within 1 minute of performing the biopsies
or pipetting the supernatant in the case of the ascitic fluid sample.
The larger section was immediately flash frozen in liquid nitro-
gen while the smaller section fixed in buffered 10% formalin.
Whole blood was collected in heparinized tubes (Vacutainer,
BD, Franklin Lakes, NJ), diluted 1:1 with 0.9% saline, after
which it was layered over ficol (Lymphoprep, Neegard,
Norway) and centrifuged at 400 xg for 30 minutes. The
Phase I Trial of the HSP90 Inhibitor 17-AAG
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lymphocytes were then isolated from the plasma-ficol interface
and resuspended in 0.9% NaCl. Cell pellets were obtained by
centrifugation (600 xg) and flash frozen in liquid nitrogen.
Western Blotting
Cell pellets were lysed in lysis buffer (0.1%Nonidet P-40), 50
mmol/L N-2-hydoxyethylpiperazine-N-2-ethanesulfonic acid
(pH, 7.4), 250 mmol/L NaCl, 1 mmol/L phenylmethylsulfonyl
fluoride, 10 g/mL aprotonin, 20ug/mL leupeptin, 1 mmol/L
dithiothreitol, 1 mmol/L EDTA, 1 mmol/L NaF, 10 mmol/L -
glycerophosphate, and 0.1 mmol/L sodium orthovanadate). Sam-
ples (50 g protein) were denatured in Laemmli loading buffer
(10% glycerol, 5% beta mercaptoethanol, 2% sodium dodecyl
sulfate, 62.5 mmol/L Tris [pH, 6.8] and 0.05% bromophenol
blue), resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and transferred onto 0.45mpolyvinylidene flu-
oride membranes (Millipore Corp, Billerica, MA). All products in
lysis and loading buffer were obtained from Sigma, Poole, United
Kingdom. Membranes were blocked in casein blocking buffer
(0.5% casein, 150 mmol/L NaCl, 10 mmol/L Tris base, 0.25
mmol/L thimerosal). They were then probed with primary anti-
bodies c-RAF-1 (SC-133, 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), HSP70 (SPA-810, 1:2,000; Stressgen, Biotechnologies,
Victoria, Canada), LCK (06-583, 1:5,000; Upstate Biotechnology,
Lake Placid, NY), CDK4 (SC-260, 1:1,000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH;MAB-374, 1:5,000; Chemicon International Inc,
Temecula, CA). Visualization of the bound primary antibody was
performed by probing with horseradish peroxidase conjugate sec-
ondary antibodies (1:1,000; AmershamBiosciences, Buckingham-
shire, United Kingdom). A semi-quantitative analysis of the
protein expression in Western blots was carried out using Image
Quant 5 (Molecular Dynamics, Amersham Biosciences, Sunny
Vale, CA). Levels of protein expression were normalized to
GAPDH and a 1.5-fold change in treatment over control was
arbitrarily considered as a significant change. Statistical analysis
was carried out using Graph Pad Prism version 3 (SanDiego, CA).
Immunohistochemistry
After tumor biopsy, approximately 20% of the tissue was
fixed in 10% buffered formalin. It was possible to detect tumor
tissue in 22 of 26 samples on hematoxylin and eosin stained
sections. For immunohistologic analysis, paraffin-embedded sec-
tions were deparaffinized with Histoclear (National Diagnostics,
Hull, United Kingdom) and rehydrated through graded alcohols.
Endogenous peroxidase was quenched with 3% hydrogen perox-
ide–methanol mixture following which sections were rinsed in
phosphate buffered saline-Tween (PBST) and preincubated with
2% blocking serum. Sections were then incubated with HSP70
antibody at 1:500 dilution (SPA-810, Stressgen, Biotechnologies,
Victoria, Canada) for 1 hour, rinsed in PBST, and then incubated
at a 1:100 ratio with secondary biotinylated horse antimouse anti-
body (Vector Laboratories, Burlingame, CA). Tissue sections were
rinsed in PBST and then incubated with avidin-biotin complex.
Sections were further rinsed in PBST and incubated with diami-
nobenzene substrate (Sigma). Tissues were finally rinsed in PBST
and water and counterstained with Mayer’s hematoxylin (Sigma)
before dehydrating in graded ethanol, clearing in Histoclear (Na-
tional Diagnostics) and mounting with glass cover slips using
DePeX (BDH; Poole).
RESULTS
Demographics
Thirty-one patients were recruited into the study, of
whom 30 received treatment (one patient experienced dis-
ease progression between registration and planned first
treatment dose). The male-female ratio was 13:17 and the
median age was 51 years (range, 27 to 66). Patients with a
wide variety of solid tumors were accrued. Patients had a
performance status of 0 to 2 (Table 1).
Dose Escalation
The starting dose was 10mg/m2 andwas doubled to 20,
40 and 80, 160, and 320 mg/m2/week (three patients per
cohort). At the dose level 320 mg/m2/week, after three
patients had been recruited, there were pharmacodynamic
(PD) changes in PBLs and plasma concentrations of 17-
AAG consistent with antiproliferative activity in preclinical
models. It was therefore decided to expand the cohort to six
patients with a view to performing pre- and post-treatment
biopsies. There was one DLT (grade 3 diarrhea) in the
expanded cohort. Because of a DLT in one of six patients at
the dose level 320 mg/m2/week, the next dose was escalated
by 40% to 450 mg/m2/week. One patient in the first cohort
of three patients at 450 mg/m2/week experienced DLTs
(grade 3 diarrhea, grade 3 ALT elevation and grade 4 AST
elevation) and the dose level was expanded to 6 patients in
whom no further DLTs were observed. Three additional
patients were recruited at the dose level 450 mg/m2/week
to further characterize pharmacodynamic changes. One
Table 1. Patient Demographic Characteristics
No. of Patients
Patients treated 30
Male-female ratio 13:17
Age, years
Median 51
Range 27-66
Performance status
0 3
1 26
2 1
Tumor type
Melanoma 11
Sarcoma 4
Breast 3
Colon 2
Mesothelioma 2
Ovary 2
Renal 1
Non–small-cell lung 1
Pancreas 1
Primary peritonial 1
Parotid 1
Unknown primary 1
Banerji et al
4154 JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by University of Queensland on March 6, 2017 from 130.102.082.080
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
additional DLT (grade 3 diarrhea) occurred in this cohort,
taking the number of patients experiencing DLTs at 450
mg/m2/week to two of nine. Although the MTD was not
reached, further dose escalation was not attempted for the
following reasons: pharmacokinetic (PK) and PD targets
had been met; the volume of infusate reached 660 to 990 mL
with infusion times ranging from15 to 200minutes/week; and
the volume of DMSO delivered each week was 25 to 40mL.
Toxicity
Toxicities during the first cycle at all dose levels are
summarized in Table 2. Grade 3 vomiting was first noted at
the dose level 80 mg/m2/week; however, because reversible
grade 3 nausea and vomiting were not considered DLTs in
the protocol, this did not necessitate dose expansion. Pa-
tients were treated with prophylactic granisetron (1 mg
administered intravenously) above this dose level; however,
one patient each at dose levels 320 and 450 mg/m2/week
developed grade 3 vomiting. Among other significant GI
toxicities, grade 3 diarrhea was noted in three patients (one
patient at 320 mg/m2/week and two patients at 450 mg/m2/
week) andwere classed asDLTs.Grade 3 or 4 hepatotoxicity
(elevated AST and/or ALT) was noted in one patient at 450
mg/m2/week during the first cycle of chemotherapy. One
additional patient developed grade 3 hepatotoxicity, but
this was not considered a DLT because it was asymptomatic
and occurred after 1 year of continuous dosing (it is ac-
cepted practice in phase I trials to consider toxicities occur-
ring in the first cycle, in this case 4 weeks, as DLTs). Both
patients received further doses of 17-AAG at reduced doses
after the transaminitis had recovered. Among other signif-
icant toxicities, grade 3 and 2 hypersensitivity reactions
were noted in three patients (two at 320 mg/m2/week and
one at 450 mg/m2/week) during the first cycle of treatment.
It was possible to control the reactions by the administra-
tion of parenteral antihistamine and steroids in all patients.
It was possible to retreat the patients at slower infusion rates
of 90 to 200 minutes. Grade 3 hypersensitivity reactions
were not classified as DLTs following review by the institu-
tional review board of Cancer Research UK because they
were considered to be due to the egg phospholipid vehicle
used to reconstitute the 17-AAG.
Clinical Efficacy
There were no documented complete or partial re-
sponses. Twopatientswithmetastaticmalignantmelanoma
achieved stable disease for prolonged periods of 15 and 35
months (confirmed by independent external review). One
patient continues to receive treatment at the time of sub-
mission (total treatment duration to date, 41 months) and
toxicity and radiologic assessment will continue.
PK Analysis
At the highest dose level, 450 mg/m2/week, plasma
concentration 120 nmol/L (the mean IC50 of 17-AAG in
the NCI 60 human tumor cell line panel) was maintained
for approximately 24 hours (Fig 1). At this dose level, the
mean volume of distribution was 142.6 L (standard devia-
tion [SD], 60.4), mean clearance was 32.2 L/h (SD, 15.3),
and themean peak plasma level was 8,998g/L (SD, 2,881).
There was a linear correlation between the dose and area
under the curve (AUC) for 17-AAG at the dose levels stud-
ied (r2 0.71; Fig 2A). Furthermore, there was also a linear
correlation between the AUCs of 17-AAG and 17-AG over
the dose levels studied (r2 .83; Fig 2C). The PK parame-
ters for 17-AAG and the active metabolite 17-AG are sum-
marized in Table 3. In the limited number of patients (n
14) in whom repeat PK sampling was performed a week
apart, there was no significant difference in the AUC of
either 17-AAG or its metabolite 17-AG (data not shown).
PD Analysis
PD markers were studied in both tumor tissue and
PBLs. The earliest PD changes demonstrable were an induc-
tion of the cochaperone HSP70 in PBLs at 6 hours when
patients were treated with 17-AAG at a dose of 80 mg/m2/
week (data not shown). At the highest dose level, 450 mg/
m2/week, PBLs were sampled in two patients for 96 hours
(Fig 3). c-RAF-1 depletion, HSP70 induction, LCK and
Table 2. Toxicity Profile During the First Cycle of Treatment in
Patients Treated With 17-AAG
Drug-Related Adverse
Event Occurring in
Cycle 1
Dose
(mg/m2)
No. of Patients (disease status)
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea 320 1 1
450 1 2
Nausea 80 1
320 1
450 4 1
Vomiting 80 1 1
320 1 1
450 3 1
Anorexia 320 1
Taste disturbance 40 1
AST 450 2 1
ALT 450 2 1
Alk phos 450 2
Fatigue 80 1 1
320 1 1
450 2
Hypersensitivity 320 1 1†
450 1
Creatinine 450 1
Headache 450 1
NOTE. Boldfaced type indicates dose-limiting toxicities.
Abbreviations: 17-AAG, 17-allylamino, 17-demethoxygeldanamcyin; Alk
phos, alkaline phosphatase.
Nausea, vomiting, and alopecia not considered a dose-limiting toxicity
as per protocol.
†Hypersensitivity was not considered a dose-limiting toxicity because
the toxicity was thought to be due to the egg phospholipid diluent and not
the drug.
Phase I Trial of the HSP90 Inhibitor 17-AAG
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CDK4 depletion was seen in two of two, two of two, two of
two and one of two patients, respectively. PBLs were also
sampled in four patients for 48 hours at the dose level 320
mg/m2/week. c-RAF-1 depletion, HSP70 induction, and
LCK and CDK4 depletion was seen in three of three infor-
mative cases (c-RAF-1 undetectable in one patient), three of
four, zero of four, and zero of four cases, respectively.
Tumor biopsies were performed at dose levels of 320 to
450 mg/m2/week, because at these doses it was possible to
achieve plasma concentrations of drug known to have ac-
tivity in preclinical models21 and demonstrate reproducible
changes in PD markers in PBLs. Twenty-four hours after
infusion of 17-AAG at doses of 320 to 450 mg/m2/week,
induction of the cochaperone HSP70 was demonstrated in
eight of nine patients, as well as the depletion of the client
proteins CDK4 from tumor biopsies in eight of nine pa-
tients. RAF-1 was detectable in the tumors of six patients
biopsied at 24 hours, and it was possible to demonstrate
depletion in four of six patients (Fig 4). The semi-
quantitative analysis of Western blots of patients biopsied
24 hours after treatment is shown in Figure 5. In order to
evaluate the duration of target inhibition, tumor biopsies
were performed 5 days after treatment in four patients
treated at a dose of 450 mg/m2/week. c-RAF-1 was ex-
pressed in the tumors of two of these patients and depletion
was demonstrated in one. In addition CDK4 depletion and
HSP70 induction were seen in two of four and zero of four
patients respectively (Fig 4). In the one patient who had a
tumor biopsy performed 3 days after treatment, c-RAF and
CDK4 depletion was demonstrated.
In three patients (patients 20, 23, and 25) in whom
PBLs and tumors were both sampled, c-RAF-1 depletion
was seen in all PBLs and in two of two cases where it was
expressed in the tumor. CDK4 depletion was seen in both
PBLs and tumors in all three patients. LCK was not
studied in tumors. HSP70 induction was seen in both
PBLs and tumors in all three cases.
Fig 1. (A) Plasma concentrations of 17-allylamino, 17-demethoxygeldanamycin
(17-AAG) in patients treated at 450 mg/m2/week. The dotted line represents
the mean IC50 of the National Cancer Institute 60 human tumor cell line
panel. (B) Plasma concentrations of the metabolite 17-AG (17-amino,
17-demethoxygeldanamycin).
Fig 2. Linearity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG)
pharmacokinetics. (A) Relationship between area under the curve (AUC) and
the dose of 17-AAG administered. (B) Relationship between the AUC of the
metabolite 17-AG (17-amino, 17-demethoxygeldanamycin) and the dose of
17-AAG administered. (C) Relationship of the AUCs of 17-AAG and 17-AG.
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Immunohistochemical staining for HSP70 was per-
formed in selected tumor samples. Figure 6 shows two cases
in which increased intracellular expression of HSP70 was
shown in melanoma tumor biopsies.
DISCUSSION
The present phase I trial of 17-AAG explored toxicity, PK
and PD profiles of 17-AAG in a once-a-week schedule.
Dose-limiting GI toxicities not amounting to a MTD were
observed. Potentially therapeutic plasma drug concentra-
tions were achieved. Molecular signatures indicative of tar-
get inhibition were demonstrable in tumor. Evidence of
potential antitumor activity was seen.
Thirty patients were treated at seven dose levels.
Patients with a wide variety tumor of types were re-
cruited. However, due to easy accessibility of tissue for
biopsy, a significant number of melanoma patients were
included (Table 2).
GI toxicities including nausea, vomiting, and diarrhea
were grade 3 toxicities observed during the trial. The for-
mulation of 17-AAG contains 4% DMSO and at higher
doses (ie, 160 to 450 mg/m2/week), the amount of DMSO
administered varied from 10 to 40 mL in a single infusion.
Although higher doses of DMSO have been administered
safely, GI toxicities, mentioned above, are known adverse
effects of DMSO22 and could have contributed to the nau-
sea, vomiting, and possibly diarrhea seen in the trial. There
was one DLT due to grade 3 to 4 hepatotoxicity at 450
mg/m2/week, and this patient had a plasma AUC higher
than other patients and went on to receive 17-AAG at 320
mg/m2/week without further hepatotoxicity. There were 2
cases of grade 3 hypersensitivity reactions documented dur-
ing the trial. All patients responded to parenteral antihista-
mines, steroids and reduction in the rate of infusion. The
grade 3 toxicities were not classified asDLTs because the egg
phospholipid diluent and not 17-AAG itself was thought to
be the contributing factor. The problem of the diluent caus-
ing hypersensitivity reactions has been encountered in
phase I trials before (eg, cremophor used in the formulation
of taxanes23,24) and such reactions, if controllable, have not
been classed asDLTs. Finally, thoughnot formally studied, the
odor of DMSO persisted in patients’ secretions for variable
lengths of time and had a negative impact on quality of life.
Fig 3. Representative Western blot analysis of serial peripheral blood leukocyte
samples following a single dose of 17-allylamino, 17-demethoxygeldanamycin
(17-AAG) at 450 mg/m2/week (Patient 25). The characteristic molecular
signature of heat shock protein 90 (HSP90) inhibition (c-RAF-1, LCK, CDK4
depletion and HSP70 induction) was seen for varying periods of time after
the infusion. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Table 3. Summary of Pharmacokinetic Parameters of 17-AAG and Its Metabolite 17-AG
Drug/Metabolite
Dose
mg/m2/week
Tmax (Hr) Cmax (g · L
1) AUC (g/hr · L1)
Clearance
(L · hr1) VDss (L)
Mean SD Mean SD Mean SD Mean SD Mean SD
17-AAG 10 0.4 0.1 315.7 115.1 311.0 72.6 51.1 5.3 173.7 40.6
20 0.4 0.1 713.4 273.0 718.4 165.7 51.9 5.9 162.5 36.6
40 0.3 0.1 1,363.2 347.3 1,741.2 442.3 43.0 17.0 120.9 33.1
80 0.6 0.3 1,899.4 446.1 2,292.0 153.7 58.6 1.2 108.9 23.1
160 0.8 0.3 4,003.2 1,132 7,979.3 5,312.2 39.5 20.6 82.2 14.8
320 1.4 1.0 6,544.4 1,407.2 20,836.6 10,631.9 33.6 20.0 91.5 18.7
450 1.2 0.4 8,998.2 2,881.5 30,087.4 14,363.9 33.2 15.3 142.6 64.2
17-AG 10 0.4 0.1 49.6 16.3 160.7 121.7 211.9 282.1 442.2 47.6
20 0.7 0.3 106.1 72.2 820.3 711.1 70.2 70.8 753.4 590.1
40 0.7 0.2 220.4 74.1 1,726.9 964.8 42.6 21.9 567.7 214.2
80 0.9 0.0 602.7 332.1 3,310.5 1,861.6 40.1 19.2 509.5 256.1
160 1.1 0.4 2,265.4 1,122.9 15,272.3 14,829.2 21.7 12.6 180.7 93.9
320 2.4 1.9 2,852.4 1,060.8 27,587.2 18,175.0 37.7 33.5 193.2 128.9
450 3.0 1.9 3,738.0 1,503.0 39,336.4 26,745.9 30.7 18.8 230.4 109.6
Abbreviations: 17-AAG, 17-allylamino, 17-demethoxygeldanamcyin; 17-AG, 17-amino, 17-demethoxygeldanamycin; Tmax, time to maximum serum
concentration; hr, hour; Cmax, maximum serum concentration; AUC, area under the curve; VDss, steady-state volume of distribution; SD, standard deviation.
Phase I Trial of the HSP90 Inhibitor 17-AAG
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This would need to be given serious consideration if patients
were to receive DMSOmore frequently than once a week.
There were no complete or partial responses recorded
during the study. However, two patients with metastatic
melanoma receiving 17-AAG achieved radiologically docu-
mented stable disease for prolonged periods (15 and 35
months), and assessment continues in one patient who has
received treatment for 41 months to date. A cytostatic
growthdelaywas themost commonly seeneffectwith17-AAG
in xenograft models.17-19,21 Disease stabilization is becoming
an increasingly important end point during evaluation of
novel agents that are often cytostatic rather than cytotoxic and
will have to be studied in carefully designed phase II trials.
Since the dose-versus-AUC relationship for 17-AAG
was linear and there was also a linear correlation between
the AUC of 17-AAG and that of its metabolite 17-AG, this
leads us to believe that, over the dose range studied (10 to
450 mg/m2/week), there was no saturation of the metabo-
lism of 17-AAG. Previous studies have shown that the cyto-
chrome P450 CYP3A4 is responsible for the metabolism of
17-AAG to 17-AG.25 The linear correlation between the
AUC of 17-AAG and that of 17-AG (Fig 2C) suggests that
CYP3A4 polymorphism is unlikely to explain variability in
17-AAG PK. At the highest dose level, 450 mg/m2/week,
plasma 17-AAG concentrations exceeded 10 mol/L. The
concentrations of drug remained above 120 nmol/L, which
is the IC50 in the NCI cell line panel, for periods in excess of
24 hours. 17-AAG concentrations achieved were also in the
range of drug concentrations shown to cause tumor growth
Fig 4. Western blot analysis of tumor samples taken before treatment and
24 to 96 hours after treatment at dose levels 320 to 450 mg/m2/week of
17-allylamino, 17-demethoxygeldanamycin (17-AAG). Results show variable
degrees of client protein suppression (c-RAF-1, CDK4) and co-chaperone
induction (heat shock protein 70 [HSP70]). (A) 320 mg/m2/week; (B) and (C)
450 mg/m2/week.
Fig 5. Semi-quantitative densitometry analysis of the data from Figure 4 in
which expression levels of proteins have been normalized to the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) signals in tumor
biopsies before and 24 hours after treatment with 17-allylamino, 17-
demethoxygeldanamycin (17-AAG). (A) c-RAF-1; (B) HSP70; and (C) CDK4.
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delay in human tumor xenograft models.21 It has also been
noted that the metabolite 17-AG is active and may contrib-
ute to the activity of 17-AAG.19 The high volume of distri-
bution is consistent with preclinical experiments suggesting
retention of both 17-AAG and its metabolite 17-AG in
tumor when compared to plasma, possibly contributing to
a viable therapeutic index.26 Thus, at the highest dose level
studied, it has been possible to achieve adequate plasma
concentrations of 17-AAG, without saturating its metabo-
lism, leaving scope for further dose expansion in a once-a-
week schedule if the formulation is improved.
One of the primary aims of this study was to determine
whether evidence of HSP90 inhibition could be obtained in
both healthy and tumor tissue in patients treated with 17-
AAG. Preclinical models suggest that depletion of client
proteins c-RAF-1 andCDK4, togetherwith the induction of
the co-chaperone HSP70, constitute a molecular signature
of HSP90 inhibition which correlates with inhibition of
growth of malignant cells both in vitro and in vivo.1 The
demonstration of reproducible PD changes in PBLs (Fig 3)
along with plasma levels of drug known to inhibit growth in
preclinical models (Fig 1) led us to biopsy patients at the
dose levels 320 to 450 mg/m2/week. PBLs were particularly
helpful in deciding at which dose level tumor biopsies
should be initiated.We were able to compare themolecular
signature of HSP90 inhibition in tumor and PBLs of the
same individual in two patients at 450mg/m2/week and one
patient at 320 mg/m2/week. c-RAF-1 depletion and HSP70
induction was seen in both PBLs and tumor in all three
patients. CDK4 depletion was seen in the tumor biopsies in
all three patients but in the PBLs of only one. The reasons
for the differences are not known. It is well established,
however, that depletion of particular client proteins by 17-
AAG can occur at different rates in different cell lines27
possibly due to the varying rates of synthesis and ubiquitin-
dependent proteasomal degradation. It was possible to
demonstrate PD changes suggestive of HSP90 inhibition in
tumor biopsies at 24 hours but not reproducibly at 96 hours
after treatment (Fig 4). This leads us to believe thatHSP90 is
inhibited in tumor for somewhere between 1 and 5 days.
Indeed in one patient in whom it was possible to obtain
biopsies at 1 and 3 days, we demonstrated sustained
c-RAF-1 and CDK4 depletion (patient 28, Fig 4). The PD
data suggest that a schedule in which 17-AAG is adminis-
tered more frequently than once a week may be needed to
inhibit the target HSP90 continuously. In fact, a daily
schedule (5 days of 7 every 3 weeks) has been assessed in
a separate phase I trial. With this schedule the MTD was 40
mg/m2/week.28 Apart from much lower drug levels in
plasma, this leaves the target uninhibited for 2 weeks at a
time. Other phase I trials are ongoing in which the drug has
been administered twice and/or three times a week; however,
concerns remain about hepatotoxicity, time spent in hospital,
DMSO-induced nausea, and persistent odor when the drug
was administeredmore frequently than once a week.
In conclusion, this phase I trial of 17-AAG has demon-
strated that it is feasible, in a once-a-week schedule, to deliver a
dose resulting in a potentially therapeutic plasma concentra-
tion, target inhibition in tumor tissue, and possible antitumor
activity (Fig 7). The present formulation of the drug does not
allow further dose escalation to establish an MTD clearly
attributable to the drug. Improvements in the formulation of
Fig 6. Immunohistochemistry for heat
shock protein 70 (HSP70) expression
(brown staining) in paired biopsy samples
before and 24 hours after treatment with
17-allylamino, 17-demethoxygeldanamycin
(17-AAG) at 450 mg/m2. Magnifications
shown for patients 26 and 27 were 100
and 200 respectively. Results show in-
creased intracellular expression of HSP70
in tumor after drug treatment.
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17-AAG would provide greater flexibility in scheduling and
the discovery of new HSP90 inhibitor chemotypes with en-
hanced physicochemical properties is ongoing.29 A dose level
of 450mg/m2/week is recommended for the present formula-
tion of 17-AAG in phase II clinical trials.
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Fig 7. Pharmacokinetic-pharmacodynamic-clinical relationship in a patient (patient 20) treated with 17-allylamino, 17-demethoxygeldanamycin (17-AAG). (A)
Peak plasma concentrations of  10 mol/L and concentrations of approximately 100 nmol/L are achieved at 24 hours. (B) Tumor biopsies taken before and
24 hours after drug administration shows CDK4 depletion and heat shock protein 70 (HSP70) induction (the tumor did not express c-RAF-1 in this case). (C)
Computed tomography scans of a left-sided submandibular metastasis of malignant melanoma 34 months apart.
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